Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

ASPIRIN LINK TO DECREASED COLORECTAL CANCER RISK SUPPORTED

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

ASPIRIN LINK TO DECREASED COLORECTAL CANCER RISK SUPPORTED by the results of a prospective cohort study of 47,900 male health professionals published in the Aug. 15 issue of Annals of Internal Medicine. The analysis of the Health Professionals Follow-Up Study, conducted by Edward Giovannucci, MD, Harvard Medical School, et al., "supports laboratory, clinical, and other epidemiological evidence that regular use of aspirin is associated with a decreased risk of colorectal cancer."

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Merck Investors Keeping A Close Watch On Winrevair Uptake

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

See All
UsernamePublicRestriction

Register

PS083107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By